The identification and characterization of conserved epitopes on the HIV-1 viral spike that are immunogenic in humans and targeted by neutralizing antibodies is an important step in vaccine design. Antibody cloning experiments revealed that 32% of all HIV-neutralizing antibodies expressed by the memory B cells in patients with high titers of broadly neutralizing antibodies recognize one or more “core” epitopes that were not defined. Here, we show that anti-core antibodies recognize a single conserved epitope on the gp120 subunit. Amino acids D474, M475, R476, which are essential for anti-core antibody binding, form an immunodominant triad at the outer domain/inner domain junction of gp120. The mutation of these residues to alanine im...
AbstractNeutralizing antibody (nAb) response is sporadic and has limited potency and breadth during ...
AbstractThe V3 loop of HIV-1 gp120 is considered occluded on many primary viruses. However, virus se...
The generation of broadly neutralizing antibodies is a priority in the design of vaccines against HI...
SummaryBroadly neutralizing monoclonal antibodies to HIV-1 are rare but invaluable for vaccine desig...
Two to three years after infection, a fraction of HIV-1–infected individuals develop serologic activ...
AbstractThe identification of cross-neutralizing antibodies to HIV-1 is important for designing anti...
Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1-infected individuals,...
Identifying the targets of broadly neutralizing antibodies to HIV-1 and understanding how these anti...
A small proportion of HIV-infected individuals generate a neutralizing antibody (NAb) response of ex...
Identifying the targets of broadly neutralizing antibodies to HIV-1 and understanding how these anti...
AbstractHuman immunodeficiency virus (HIV-1) enters target cells by binding its gp120 exterior envel...
Current HIV-1 vaccines elicit strain-specific neutralizing antibodies. However, cross-reactive neutr...
Major advances in donor identification, antigen probe design, and experimental methods to clone path...
A comprehensive understanding of the regions on HIV-1 envelope trimers targeted by broadly neutraliz...
HIV-1 broadly neutralizing antibodies are desired for their therapeutic potential and as templates f...
AbstractNeutralizing antibody (nAb) response is sporadic and has limited potency and breadth during ...
AbstractThe V3 loop of HIV-1 gp120 is considered occluded on many primary viruses. However, virus se...
The generation of broadly neutralizing antibodies is a priority in the design of vaccines against HI...
SummaryBroadly neutralizing monoclonal antibodies to HIV-1 are rare but invaluable for vaccine desig...
Two to three years after infection, a fraction of HIV-1–infected individuals develop serologic activ...
AbstractThe identification of cross-neutralizing antibodies to HIV-1 is important for designing anti...
Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1-infected individuals,...
Identifying the targets of broadly neutralizing antibodies to HIV-1 and understanding how these anti...
A small proportion of HIV-infected individuals generate a neutralizing antibody (NAb) response of ex...
Identifying the targets of broadly neutralizing antibodies to HIV-1 and understanding how these anti...
AbstractHuman immunodeficiency virus (HIV-1) enters target cells by binding its gp120 exterior envel...
Current HIV-1 vaccines elicit strain-specific neutralizing antibodies. However, cross-reactive neutr...
Major advances in donor identification, antigen probe design, and experimental methods to clone path...
A comprehensive understanding of the regions on HIV-1 envelope trimers targeted by broadly neutraliz...
HIV-1 broadly neutralizing antibodies are desired for their therapeutic potential and as templates f...
AbstractNeutralizing antibody (nAb) response is sporadic and has limited potency and breadth during ...
AbstractThe V3 loop of HIV-1 gp120 is considered occluded on many primary viruses. However, virus se...
The generation of broadly neutralizing antibodies is a priority in the design of vaccines against HI...